3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
12
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
40
Lymphoma, Non-Hodgkin
39
Lymphoma, Follicular
24
Lymphoma
22
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Mantle-Cell
18
Lymphoma, B-Cell
10
Recurrence
9
Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
6
Hodgkin Disease
6
Multiple Myeloma
4
Hematologic Diseases
4
Lymphoma, T-Cell, Peripheral
3
Advanced Solid Tumor
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Interventions
zanubrutinib
9
ibrutinib
9
Rituximab
5
idelalisib
4
venetoclax
3
pirtobrutinib
3
ublituximab
2
bazlitoran
2
acalabrutinib
2
Dexamethasone
2
ARQ531
2
umbralisib
1
selinexor
1
sapanisertib
1
pomalidomide
1
perifosine
1
pembrolizumab
1
ontuxizumab
1
ofatumumab
1
obinutuzumab
1
mavorixafor
1
loncastuximab tesirine
1
fludarabine
1
epratuzumab
1
enzastaurin
1
carfilzomib
1
brexucabtagene autoleucel
1
WW Domain-Containing Oxidoreductase
1
Voriconazole
1
Vitamin B 12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Waldenstrom Macroglobulinemia
×
Bendamustine Hydrochloride
×
Clear all
NCT01732926
2018-11-16
Bridalveil
Gilead Sciences
Phase 3
Terminated
475 enrolled
9 charts